Galmed Pharmaceuticals
GLMD
11 hedge funds and large institutions have $11.4M invested in Galmed Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
76% more capital invested
Capital invested by funds: $6.52M → $11.4M (+$4.93M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0.01% more ownership
Funds ownership: 0.05% → 0.06% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$576K |
| 2 |
GL
GLG LLC
New York
|
+$457K |
| 3 |
6CM
683 Capital Management
New York
|
+$379K |
| 4 |
Morgan Stanley
New York
|
+$195K |
| 5 |
LNWWM
Laird Norton Wetherby Wealth Management
San Francisco,
California
|
+$77.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$116K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$48K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
1
683 Capital Management
New York
| $5.02M | +$379K | +274 | +10% |
|
|
PWAM
2
Park West Asset Management
San Francisco,
California
| $2.56M | +$576K | +416 | +36% |
|
|
GL
3
GLG LLC
New York
| $1.36M | +$457K | +330 | +65% |
|
|
4
Morgan Stanley
New York
| $1.11M | +$195K | +141 | +26% |
|
|
PAWC
5
P.A.W. Capital
Greenwich,
Connecticut
| $960K | -$116K | -84 | -13% |
|
|
SKK
6
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| $167K | – | – | – |
|
|
CA
7
CapWealth Advisors
Franklin,
Tennessee
| $108K | – | – | – |
|
|
LNWWM
8
Laird Norton Wetherby Wealth Management
San Francisco,
California
| $91K | +$77.5K | +56 | New |
|
9
Acadian Asset Management
Boston,
Massachusetts
| $57K | +$48.4K | +35 | New |
|
10
JP Morgan Chase
New York
| $5K | +$4.15K | +3 | New |
|
|
RFA
11
Reilly Financial Advisors
La Mesa,
California
| $2K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$48K | -43 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$1K | -1 | Closed |
|
GLMD Hedge Fund Activity: Q3 2017 in Review
11 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2017, worth a combined $11.4M — up 76% from $6.52M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GLMD positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Park West Asset Management, adding an estimated $576K. The largest seller was P.A.W. Capital, cutting an estimated $116K.
- 11 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2017, up from 10 in Q2 2017.
- Funds reported $11.4M of Galmed Pharmaceuticals stock for Q3 2017, up 76% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of +1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2017 was Park West Asset Management, an estimated $576K added.
- The largest Galmed Pharmaceuticals seller in Q3 2017 was P.A.W. Capital, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2017.